Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ross Camidge

Showing results (21-30 of 317) with videos related to

Pageof 32
Sort By:
Nature Reviews. Clinical Oncology|April 5, 2012
Treating ALK-positive lung cancer--early successes and future challengesD Ross Camidge, Robert C Doebele
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 21, 2023
Editorial Related to Leeuw et al.: The Evolution of Expectations: How Our Views On "Acceptable" Toxicities Are Changing With Prolonged Lung Cancer TreatmentsJohn Michael Taormina, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2012
Targeting ALK, ROS1, and BRAF kinasesRobert C Doebele, D Ross Camidge
Journal of Thoracic Disease|January 16, 2015
Buyer beware: understanding the assumptions behind health economic assessments in personalized cancer careD Ross Camidge, Adam J Atherly
Translational Lung Cancer Research|December 3, 2015
PROFILE 1014: lessons for the new era of lung cancer clinical researchSinead A Noonan, D Ross Camidge
Cell|October 16, 2020
Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung CancerD Ross Camidge, Erin L Schenk
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2011
Apoptotic pathway manipulationD Ross Camidge, Andrew M Thorburn
The Lancet. Oncology|November 28, 2017
Lung cancer's real adjuvant EGFR targeted therapy questionsTerry L Ng, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2017
Reviewing RECIST in the Era of Prolonged and Targeted TherapyRustain L Morgan, D Ross Camidge
Translational Lung Cancer Research|January 5, 2018
KEYNOTE-028: how do we use immunotherapy in small cell lung cancer?Jose M Pacheco, D Ross Camidge
Pageof 32

Showing results (21-30 of 317) with videos related to

Sort By:
Pageof 32
Nature Reviews. Clinical Oncology|April 5, 2012
Treating ALK-positive lung cancer--early successes and future challengesD Ross Camidge, Robert C Doebele
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 21, 2023
Editorial Related to Leeuw et al.: The Evolution of Expectations: How Our Views On "Acceptable" Toxicities Are Changing With Prolonged Lung Cancer TreatmentsJohn Michael Taormina, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2012
Targeting ALK, ROS1, and BRAF kinasesRobert C Doebele, D Ross Camidge
Journal of Thoracic Disease|January 16, 2015
Buyer beware: understanding the assumptions behind health economic assessments in personalized cancer careD Ross Camidge, Adam J Atherly
Translational Lung Cancer Research|December 3, 2015
PROFILE 1014: lessons for the new era of lung cancer clinical researchSinead A Noonan, D Ross Camidge
Cell|October 16, 2020
Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung CancerD Ross Camidge, Erin L Schenk
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2011
Apoptotic pathway manipulationD Ross Camidge, Andrew M Thorburn
The Lancet. Oncology|November 28, 2017
Lung cancer's real adjuvant EGFR targeted therapy questionsTerry L Ng, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2017
Reviewing RECIST in the Era of Prolonged and Targeted TherapyRustain L Morgan, D Ross Camidge
Translational Lung Cancer Research|January 5, 2018
KEYNOTE-028: how do we use immunotherapy in small cell lung cancer?Jose M Pacheco, D Ross Camidge
Pageof 32